Content continues after advertisement

Research Note: Babesiosis Vaccine Antigens

Preventive Medicine

|April 2018

Sign in to Print/View PDF

Existing commercial vaccines against babesiosis contain soluble parasite antigens (SPAs) from in vitro culture supernatants of Babesia canis. This study identified and characterized the specific antigen in SPA serum that confers immunity in vaccinated dogs (ie, canine Babesia antigen [CBA]) and sequenced the gene that encodes it. The gene was then cloned and expressed in Escherichia coli. The recombinant CBA (rCBA) was found to protect against challenge infection in rCBA-vaccinated dogs. The rCBA antigen could replace existing SPA vaccines, thereby eliminating the need for dog blood and serum for production of vaccine.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy